Genetic Engineering & Biotechnology News

SEP15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/869753

Contents of this Issue

Navigation

Page 42 of 77

The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both diffi cult and very expensive to implement. Using HEK293 it has been demonstrated that addition of recombinant human insulin to commercially available chemically defi ned media, can be used as a supplement to increase VCD and specifi c viral yield. To learn more visit www.novonordiskpharmatech.com Increase specifi c Infl uenza production with recombinant human insulin *Data kindly supplied by Aziza Manceur, National Research Council Canada. Hemagglutinin (HA) assay is used for quantifi cation of Infl uenza (H1N1). Insulin Human AF used in the experiments is supplied by Novo Nordisk Pharmatech. CD 293 media is trademark of Thermo Fisher Scientifi c. Consistency. Proven Insulin concentration (mg/L) 40 HA concentration (ug/mL) Infl uenza production in HEK293 30 20 10 0 0 5 10 25 50 100 Insulin concentration (mg/L) 10 Total cell count (E05 cells/mL) HEK293 cells in CD 293 media * 8 6 4 2 0 0 5 10 25 50 100

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - SEP15 2017